Vulvodynia Treatment Drug Market Set to Surge by 2037
The vulvodynia treatment drug market is predicted to have increased from its value of more than USD 6.9 billion in 2024 to about USD 15.2 billion by the end of 2037. The forecast period (2025–2037) has a compound annual growth rate (CAGR) of 6.8% in this increase. Market growth is being driven by rising awareness of vulvodynia as a chronic pain condition, increasing diagnoses globally, and ongoing advancements in pharmaceutical interventions targeting neuropathic pain and inflammation. Vulvodynia Treatment Drug Industry Demand Vulvodynia is a chronic, unexplained pain or discomfort around the vulva, often described as burning, stinging, or irritation without an identifiable cause. It can significantly impact the quality of life, sexual health, and psychological well-being of affected individuals—primarily women of reproductive and postmenopausal age. As awareness of women's pelvic pain disorders increases, the need for effective therapeutic solutions has gained global tra...